Rein Therapeutics Inc. (RNTX) has a negative trailing P/E of -0.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -131.54%, forward earnings yield 26.39%.
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2017 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2018 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2019 | 0.0 | 0.00 | 0.00 | 0.00 | - |
| 2020 | -1,746.5 | 0.00 | 3.04 | 0.00 | - |
| 2021 | -359.8 | 0.00 | 0.21 | 0.00 | - |
| 2022 | -352.1 | -159.53 | 0.52 | 0.00 | - |
| 2023 | -619.6 | 14.35 | 1.42 | 0.00 | - |
| 2024 | -0.7 | -0.25 | 0.76 | 0.00 | - |
| 2025 | -0.6 | 0.01 | 1.74 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2020 | $-12.14 | $0.00 | $-21.16K | - |
| 2021 | $-5.89 | $0.00 | $-26.16K | - |
| 2022 | $-6.02 | $0.00 | $-27.33K | - |
| 2023 | $-3.42 | $0.00 | $-15.73K | - |
| 2024 | $-3.51 | $0.00 | $-62.88M | - |
| 2025 | $-1.96 | $0.00 | $-49.87M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.80 | $-0.80 – $-0.80 | $69.76M | $69.76M – $69.76M | 1 |
| 2027 | $-0.92 | $-0.92 – $-0.92 | $127.66M | $127.66M – $127.66M | 1 |
| 2028 | $-1.15 | $-1.15 – $-1.15 | $0.00 | $0.00 – $0.00 | 1 |
| 2029 | $-0.94 | $-0.94 – $-0.94 | $0.00 | $0.00 – $0.00 | 1 |
| 2030 | $0.43 | $0.43 – $0.43 | $144.1M | $144.1M – $144.1M | 1 |
